Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CCR7 monoclonal antibody CAP-100

A humanized immunoglobulin G1 (IgG1) monoclonal antibody against C-C-chemokine receptor 7 (CCR7), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CCR7 monoclonal antibody CAP-100 targets and binds to CCR7 on tumor cells, and neutralizes ligand-mediated signaling through both ligands CCL19 and CCL21. This prevents the activity of CCR7 on tumor cells. CAP-100 is expected to prevent the migration of tumor cells to and their survival in lymphoid niches. In addition, CAP-100 eliminates CCR7-positive tumor cells via the induction of Fc-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). CCR7, a G-protein coupled receptor involved in trafficking of cells to lymph nodes, is normally expressed by subsets of immune cells and overexpressed in various types of cancer cells, such as in many hematological malignancies. Its overexpression has been associated with lymph node metastasis and poor survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:CAP 100
CAP-100
CAP100
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search